Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in CML-CP Patients With Low Imatinib Trough Levels
NCT01131325Phase 4Terminated
- Sponsor
- Novartis
- Start
- Oct 2010
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Novartis. Primary endpoint: Number of Treatment Failure Events at 2 years. Started Oct 2010; status: terminated.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01131325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01131325.